GILD - Gilead Sciences, Inc.
NEXT EARNINGS:
Apr 23, 2026
EPS Est: $1.84
|
Rev Est: $6.9B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$157.38
DETAILS
HIGH:
$177.00
LOW:
$105.00
MEDIAN:
$161.00
CONSENSUS:
$157.38
UPSIDE:
6.60%
Market Cap:
183.17B
Volume:
8,137,554
Avg Volume:
7,284,003
52 Week Range:
93.37-157.29
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.39
Last Dividend:
$3.16
Exchange:
NASDAQ
Country:
US
Employees:
17,600
IPO Date:
1992-01-22
EPS (TTM):
6.84
P/E Ratio:
17.94
Revenue (TTM):
29.44B
Total Assets:
59.02B
Total Debt:
N/A
Cash & Equiv:
N/A
Rev Growth (5Y):
3.6%
EPS Growth (5Y):
133.8%
FCF Growth (5Y):
5.9%
ROCE:
22.9%
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-10 | $1.86 | $1.81 | +2.8% | $7.9B | $7.7B | +3.1% |
| 2025-10-30 | $2.47 | $2.13 | +16.0% | $7.8B | $7.4B | +4.3% |
| 2025-08-07 | $2.01 | $1.96 | +2.6% | $7.1B | $7.0B | +1.4% |
| 2025-04-24 | $1.81 | $1.78 | +1.7% | $6.7B | $6.8B | -2.1% |
| 2025-02-11 | $1.90 | $1.74 | +9.2% | $7.6B | $7.2B | +5.8% |
| 2024-11-06 | $2.02 | $1.53 | +32.0% | $7.5B | $7.0B | +7.5% |
| 2024-08-08 | $2.01 | $1.61 | +24.8% | $6.9B | $6.7B | +3.7% |
| 2024-04-25 | $-1.32 | $-1.49 | +11.4% | $6.7B | $6.4B | +5.2% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.44B | 28.75B | 27.12B | 27.28B | 27.30B | 24.69B | 22.45B | 22.13B | 26.11B | 30.39B | 32.64B | 24.89B |
| Net Income | 8.51B | 480.00M | 5.67B | 4.59B | 6.22B | 123.00M | 5.39B | 5.46B | 4.63B | 13.50B | 18.11B | 12.10B |
| EPS | 6.84 | 0.38 | 4.54 | 3.66 | 4.96 | 0.10 | 4.24 | 4.20 | 3.54 | 10.08 | 12.37 | 7.95 |
| Total Assets | 59.02B | 58.99B | 62.12B | 63.17B | 67.95B | 68.41B | 61.63B | 63.67B | 70.28B | 56.98B | 51.72B | 34.66B |
| Total Debt | 0 | 26.71B | 24.99B | 25.23B | 26.70B | 31.40B | 24.59B | 27.32B | 33.54B | 26.35B | 22.05B | 12.40B |
| Cash & Equivalents | 0 | 9.99B | 6.08B | 5.41B | 5.34B | 6.00B | 11.63B | 17.94B | 7.59B | 8.23B | 12.85B | 10.03B |
| Operating Cash Flow | 10.02B | 10.83B | 8.01B | 9.07B | 11.38B | 8.17B | 9.14B | 8.40B | 11.90B | 17.05B | 21.25B | 12.82B |
| Free Cash Flow | 10.02B | 10.30B | 7.42B | 8.34B | 10.80B | 7.52B | 8.32B | 7.48B | 11.31B | 16.30B | 20.50B | 12.26B |
| FCF per Share | 8.05 | 8.26 | 5.95 | 6.65 | 8.60 | 5.98 | 6.55 | 5.76 | 8.65 | 12.17 | 14.00 | 8.06 |
| Book Value | 22.62B | 19.33B | 22.83B | 21.24B | 21.07B | 18.20B | 22.52B | 21.39B | 20.44B | 18.89B | 18.53B | 15.43B |
| Cash & ST Investments | 10.61B | 11.57B | 7.26B | 6.38B | 6.52B | 7.41B | 24.35B | 30.09B | 25.51B | 11.89B | 14.61B | 10.13B |
| ROC Equity | 0.38 | 0.02 | 0.25 | 0.22 | 0.30 | 0.01 | 0.24 | 0.26 | 0.23 | 0.71 | 0.98 | 0.78 |